Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
12 août 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
01 août 2024 16h05 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
01 août 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
29 juil. 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
31 mai 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
29 mai 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
21 mai 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
17 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
05 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
03 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis